Loading...
Loading...
STOK| Name | Value |
|---|---|
| Revenues | 2.8M |
| Cost of Revenue | 1.2M |
| Gross Profit | 1.6M |
| Operating Expense | 31.2M |
| Operating I/L | -29.6M |
| Other Income/Expense | 2.6M |
| Interest Income | 2.6M |
| Pretax | -27.0M |
| Income Tax Expense | 10.7M |
| Net Income/Loss | -27.0M |
Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company specializing in developing novel antisense oligonucleotide (ASO) medicines to treat severe genetic diseases. The company's proprietary Targeted Augmentation of Nuclear Gene Output technology enables the precise upregulation of protein expression. Its lead clinical candidate, STK-001, is in a phase I/IIa clinical trial for Dravet syndrome, while STK-002 is in the preclinical stage for autosomal dominant optic atrophy treatment. Stoke has a license and collaboration agreement with Acadia Pharmaceuticals Inc. to develop and commercialize RNA-based medicines for severe and rare genetic neurodevelopmental diseases of the central nervous system.
